398 related articles for article (PubMed ID: 17641984)
41. Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score.
Guerrero AL; Laherrán E; Gutiérrez F; Martín-Polo J; Iglesias F; Alcázar C; Peralta J; Rostami P
Acta Neurol Scand; 2008 Jan; 117(1):21-5. PubMed ID: 17883422
[TBL] [Abstract][Full Text] [Related]
42. [Long-term effects of glatiramer acetate in multiple sclerosis].
Brochet B
Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
[TBL] [Abstract][Full Text] [Related]
43. Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis.
Young PJ; Lederer C; Eder K; Daumer M; Neiss A; Polman C; Kappos L;
Neurology; 2006 Sep; 67(5):804-8. PubMed ID: 16966541
[TBL] [Abstract][Full Text] [Related]
44. [The comparison of the effectiveness of treatment of multiple sclerosis relapse with high doses of methylprednisolone, alpha-24 corticotropin and cyclophosphamide].
Paradowski B; Gruszka E; Pokryszko A
Pol Merkur Lekarski; 1999 Jun; 6(36):305-7. PubMed ID: 10481540
[TBL] [Abstract][Full Text] [Related]
45. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.
van de Wyngaert FA; Beguin C; D'Hooghe MB; Dooms G; Lissoir F; Carton H; Sindic CJ
Acta Neurol Belg; 2001 Dec; 101(4):210-6. PubMed ID: 11851027
[TBL] [Abstract][Full Text] [Related]
46. [Therapeutic efficacy during active phases of multiple sclerosis: gait analysis and comparison with the EDSS score].
Fauchard-Renard C; Renard JF; Miret N; Hannequin D; Mihout B; Weber J
Rev Neurol (Paris); 2001 Jul; 157(6-7):649-54. PubMed ID: 11458184
[TBL] [Abstract][Full Text] [Related]
47. Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses.
Ramo-Tello C; Tintoré M; Rovira A; Ramió-Torrenta L; Brieva L; Saiz A; Cano A; Carmona O; Hervás JV; Grau-López L
Mult Scler; 2016 Jan; 22(1):117-21. PubMed ID: 26540732
[TBL] [Abstract][Full Text] [Related]
48. Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis.
Markianos M; Koutsis G; Evangelopoulos ME; Mandellos D; Karahalios G; Sfagos C
J Neurochem; 2009 Jan; 108(1):158-64. PubMed ID: 19014375
[TBL] [Abstract][Full Text] [Related]
49. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
50. [Determination of CSF guanase activity in multiple sclerosis: a comparative study on various parameters to monitor the disease activity].
Kaneshige Y; Matsumoto H; Chiba S; Hashimoto S; Noro H
Rinsho Shinkeigaku; 1989 Jul; 29(7):854-8. PubMed ID: 2805507
[TBL] [Abstract][Full Text] [Related]
51. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study.
Flechter S; Vardi J; Finkelstein Y; Pollak L
Isr Med Assoc J; 2007 Jun; 9(6):457-9. PubMed ID: 17642394
[TBL] [Abstract][Full Text] [Related]
52. Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids.
Muley SA; Kelkar P; Parry GJ
Arch Neurol; 2008 Nov; 65(11):1460-4. PubMed ID: 19001164
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting.
Singhal BS; Geeta S; Hundalani SG; Menon S
Neurol India; 2009; 57(4):418-23. PubMed ID: 19770542
[TBL] [Abstract][Full Text] [Related]
54. [Interferon-beta response in multiple sclerosis associated with pre-treatment disability].
Fernandez-Fernandez O; Fernandez-Sanchez VE; Mayorga C; Guerrero-Fernandez M; Leon A; Tamayo-Toledo JA; Alonso A; Romero F; Leyva L; Luque G; de Ramon E
Rev Neurol; 2006 Sep 16-30; 43(6):322-9. PubMed ID: 16981161
[TBL] [Abstract][Full Text] [Related]
55. Driving behaviors among community-dwelling persons with multiple sclerosis.
Schultheis MT; Weisser V; Manning K; Blasco A; Ang J
Arch Phys Med Rehabil; 2009 Jun; 90(6):975-81. PubMed ID: 19480873
[TBL] [Abstract][Full Text] [Related]
56. [Mitoxantrone for the treatment of Japanese patients with multiple sclerosis].
Komori M; Tanaka M; Muramoto E; Ohno M; Matsumoto R; Murase N; Kitagawa N; Saida T
Rinsho Shinkeigaku; 2007 Jul; 47(7):401-6. PubMed ID: 17710882
[TBL] [Abstract][Full Text] [Related]
57. Myelopathies secondary to Sjögren's syndrome: treatment with monthly intravenous cyclophosphamide associated with corticosteroids.
de Seze J; Delalande S; Fauchais AL; Hachulla E; Stojkovic T; Ferriby D; Hatron PY; Vermersch P
J Rheumatol; 2006 Apr; 33(4):709-11. PubMed ID: 16583474
[TBL] [Abstract][Full Text] [Related]
58. Multimodal evoked potentials measure and predict disability progression in early relapsing-remitting multiple sclerosis.
Jung P; Beyerle A; Ziemann U
Mult Scler; 2008 May; 14(4):553-6. PubMed ID: 18562509
[TBL] [Abstract][Full Text] [Related]
59. Temporal evolution of remission following multiple sclerosis relapse and predictors of outcome.
Hirst CL; Ingram G; Pickersgill TP; Robertson NP
Mult Scler; 2012 Aug; 18(8):1152-8. PubMed ID: 22217582
[TBL] [Abstract][Full Text] [Related]
60. Does neurorehabilitation have a role in relapsing-remitting multiple sclerosis?
Liu C; Playford ED; Thompson AJ
J Neurol; 2003 Oct; 250(10):1214-8. PubMed ID: 14586605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
